Moleculin Biotech, Inc. (MBRX) is an innovative, clinical-stage pharmaceutical company committed to the development of breakthrough, oncology-focused drugs. Established in 2007 and headquartered in Houston, Texas, Moleculin has created an impressive portfolio of anti-cancer drug candidates, significantly contributing to the fight against cancer.
Moleculin's primary focus is on creating a diverse pipeline of innovative drugs targeting highly resistant tumors and aggressive forms of cancer. These drug candidates showcased promising potential in the treatment of certain cancers, including pancreatic, lung, brain, and acute myeloid leukemias.
One of Moleculin's most pioneering projects is the molecule Annamycin. Unlike conventional treatments, which often have limited success due to multidrug resistance, Annamycin is designed to be immune to this resistance, presenting a potential game-changer in cancer treatment. Annamycin is currently under clinical trial for treatment of relapsed or refractory acute myeloid leukemia, and has been granted Orphan Drug Designation in the U.S. and Europe.
Another novel candidate in Moleculin's portfolio includes WP1066, crafted to manipulate the cellular signaling processes that stimulate the growth of tumors. This powerful agent has demonstrated effectiveness against a broad range of cancers, including brain tumors. It also has the potential use in treating pediatric brain tumors and has been included in the U.S. FDA's Pediatric Rare Disease Designation and Orphan Drug Designation.
Moleculin additionally explores a unique subclass of compounds known as Immune/Transcription Modulators which can stimulate the immune response against tumors. Its WP1122 drug is creating a buzz, being evaluated for its potential use against COVID-19 due to its glucose inhibition properties.
The company's ongoing commitment to cancer research as well as its dynamic approach in merging science with investors makes Moleculin a dramatic presence in oncology. The unity of entrepreneurial aptitude and scientific exploration ensured steady growth of Moleculin Biotech, Inc. on the global pharmaceutical market.
Moreover, Moleculin's pioneering work is widely recognized and backed by the U.S. Food and Drug Administration's (FDA) designations, which aids the company's clinical development of its drug candidates. With a robust pipeline of promising anti-cancer drugs, buoyed by critical regulatory support, Moleculin Biotech, Inc., is indeed well-positioned to drive key advances in oncology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Moleculin announced that an abstract detailing the first interim results from its pivotal MB-108 Phase 2/3 trial for Annamycin was accepted for presentation at the 2026 ASH Annual Meeting. The data showed higher complete remission rates in the Annamycin arms (43% and 36%) compared to placebo (12%) in the first 45 randomized patients. The independent Data Monitoring Committee recommended the trial continue unchanged, with a second interim analysis expected in early 2027.
Moleculin Biotech, Inc. announced that data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology Annual Meeting. The abstract highlights encouraging remission rates in patients with relapsed or refractory AML from the first interim analysis of its pivotal MB-108 Phase 2/3 trial. The independent Data Monitoring Committee recommended the study continue without amendment, noting no signs of cardiotoxicity.